Today, NNE published its annual report for 2024, showcasing another year of remarkable achievements, financial momentum and growth.
Group sales increased 39%, reaching DKK 4,043 million, with an operating profit margin of 12%. Our group operating profit rose to DKK 502 million, also up 39% from 2023, marking one of our strongest performances to date.
Commenting on our 2024 performance, Christoffer Hviid, Chief Financial Officer at NNE, says: "NNE's continued growth is a testament to our cross-disciplinary competencies and project execution as well as disciplined cost management and higher-than-expected utilisation."
In terms of employee engagement, we ranked in the top 10% for overall engagement throughout 2024, measured against global industry benchmarks.
"I would like to thank my colleagues for bringing their passion to work every day and our external stakeholders for our strong and continuing collaboration," adds Christoffer Hviid.
In summary, NNE closes the books on 2024 with a robust portfolio of projects and a record-high order backlog. In 2025, we will continue to focus on delivering some of the world’s largest and most advanced active pharmaceutical ingredient (API) manufacturing facilities to Novo Nordisk.
👉 Click here to read the annual report.
